Treatment Of Allergic Dermatitis Research Articles

A Network Pharmacology Study on Mechanism of Total Flavonoids of Hippophae Rhamnoides in Treating Allergic Dermatitis via Regulation of IL-17 Signaling Pathways

Objective: This study aims to investigate the active ingredients and potential mechanisms of Total Flavonoids of Hippophae (TFH) in the treatment of Allergic Dermatitis (AD) using network pharmacology and molecular docking. Methods: The effective components and targets of TFH were identified using the TCMSP, Pub- Chem, and Pharmmapper databases. AD-related targets were screened through GeneCards, OMIM, and TTD databases, leading to the identification of TFH anti-AD related targets. The STRING database was utilized to obtain protein interaction relationships, and Cytoscape 3.9.0 software was employed to construct the protein-protein interaction network. GO and KEGG enrichment analyses were conducted to elucidate the biological processes and pathways involved. Molecular docking between key components and key targets was verified using AutoDock Tools 1.5.6 software. Results: The key components identified for anti-AD activity were Quercetin, Kaempferol, Cianidanol, and Epicatechin, while the key targets included MAPK8, MAPK10, MAPK14, AKT1, SRC, and EGFR. GO analysis indicated that TFH's anti-AD effects are primarily associated with hormone regulation, cellular processes, response to stimuli, organelles, and cytoplasm. KEGG enrichment analysis suggested that the key pathways involved are pathways in cancer, lipid and atherosclerosis, and the IL-17 signaling pathway, with a significant emphasis on the IL-17 signaling pathway. Molecular docking results demonstrated that the key active ingredients exhibited strong binding activity with all the key targets, with the highest binding affinities observed between kaempferol and MAPK14, epicatechin and MAPK14, and quercetin and AKT1. Conclusion: TFH exerts therapeutic effects on atopic dermatitis through multi-component, multitarget, and multi-pathway mechanisms involving inflammatory response, immune regulation, and apoptosis. This study provides valuable insights for the further development of drugs specifically targeting AD.

Possibilities of phytotherapy for allergic dermatitis complicated by pyoderma

It was established that a water extract based on collection in combination with an antibiotic and an antihistamine preparation promotes resorption of a purulent-inflammatory process in experimental dermatitis. Water extract based on collection No. 1 in combination with an antibiotic and an antihistamine drug has a pronounced anti-inflammatory and antibacterial effect and can be used in the treatment of allergic dermatitis with opportunistic infection.

犬のアレルギー性皮膚炎に対する治療における飼い主満足度関連因子の探索

犬のアレルギー性皮膚炎に対する治療における飼い主満足度関連因子の探索

Левоцетиризин в комплексном лечении больных аллергическим дерматитом

Allergic dermatitis is one of the most common skin diseases. Pathogenically, allergic dermatitis is a delayed hypersensitivity reaction. Allergic dermatitis is provoked by various agents that penetrate the skin. More than 3,500 potential contact allergens were described. The immune response in allergic dermatitis is conventionally characterized by two phases, afferent and efferent. Treatment for allergic dermatitis includes topical and systemic therapies (antihistamines) and physiotherapy. The authors address their experience with the management of patients with allergic dermatitis. Twenty-eight patients were enrolled. The predominant clinical manifestations were erythematous lesions, infiltration, and vesicles associated with itching. All patients received levocetirizine 5 mg daily and topical steroids (methylprednisolone acetate propionate) for 10–15 days. After 2 weeks, this treatment resulted in complete symptom relief. Complex treatment for allergic dermatitis (levocetirizine 5 mg daily and topical steroids) is effective against all clinical symptoms, including itching. KEYWORDS: allergic dermatitis, treatment, antihistamines, levocetirizine, visual analogue scale, Dermatology Life Quality Index. FOR CITATION: Kruglova L.S., Bakulev A.L. Levocetirizine for the complex treatment of allergic dermatitis. Russian Medical Inquiry. 2022;6(2):105–109 (in Russ.). DOI: 10.32364/2587-6821-2022-6-2-105-109.

A clinical case of borderline leprosy

Background. Described a rare case of leprosy, borderline form in the active stage.
 Aim. To present a clinical case of the development of leprosy with atypical manifestations in a patient outside a region endemic for leprosy.
 Case report. A 67-year-old patient from 2018 to 2020 received treatment for allergic dermatitis, pyoderma, no effect was observed; in 2020 he was examined for sarcoidosis, the diagnosis was not confirmed. In the Leprosy Research Institute, an examination was carried out, including a bacterioscopic examination of skin scarificates, a pathomorphological examination of skin biopsies, and molecular genetic methods.
 Results. Based on complaints, anamnesis, examination data and physical examination, the results of clinical and laboratory examination, the diagnosis was made: leprosy, borderline form (ICD-10 A30.3), active stage.
 Conclusion. The presented observation indicates that the variety of clinical manifestations of leprosy and the lack of alertness in relation to this disease, about the difficulty in establishing the correct clinical diagnosis in the patient, given the lack of history of data on contact with patients with leprosy.

Herbal medicine for allergic dermatitis complicated by pyoderma

It has been determined that a water extract based on herbal mixture No. 1 in combination with antibiotic and antihistamine promotes resolution of purulent-inflammatory process in experimental dermatitis. Water extract based on herbal mixture No. 1 in combination with antibiotic and antihistamine has a pronounced anti-inflammatory and antibacterial effect and can be used in the treatment of allergic dermatitis with opportunistic infection.

Modern aspects of treatment of allergic dermatitis with the secondary fungal infections

Allergic skin disease pathology is widespread in the world and in the last decade has attracted the attention of doctors. In Ukraine, 40 % of adults and children suffer from all types of allergic dermatitis. The aim of this work is to study the current state of treatment of allergic dermatitis complicated with the secondary fungal infection, and substantiate the necessity for creating the extemporaneous ointment for the treatment of this skin pathology. The known recommendations of doctors concerning the treatment of allergic dermatitis include measures aimed at excluding or reducing a contact with a variety of triggers, skin care (permanent cleaning and moisturizing) and the treatment of pruritus and chronic inflammation with anti-inflammatory medicines depending on the severity, localization of lesions of the skin, as well as skin infections associated with allergic dermatitis. In addition to the systemic therapy, the topical treatment of affected areas of the skin is also recommended for patients with allergic dermatitis. The external therapy should be carried out taking into account the clinical form and stages of the disease. To analyze the existing extemporaneous formulations for the treatment of allergic dermatitis complicated with the secondary fungal infection prescriptions of various soft medicinal forms for treating allergic dermatitis approved by the Ministry of Public Health of Ukraine have been studied. The absence of antifungal components in their composition has been shown. The necessity of creating a new extemporaneous ointment for the treatment of allergic dermatitis complicated with the secondary fungal infection with the complex anti-allergic and antifungal action using a dry extract of licorice root, essential oil of lavender and terbinafine hydrochloride has been substantiated.

Substantiation of the active ingredients rational concentration of ointment for treatment of allergic dermatitis complicated by fungal infection

Aim. Due to the rapid growth of number of allergic skin diseases complicated by secondary fungal infection, creation of new drugs with an integrated anti-allergic and anti-fungal action for their local treatment is especially important.Methods and results. In the process of developing an ointment under conventional name “Allergolik” microbiological studies have been conducted to determine its rational composition. Concentrations of licorice root extract, terbinafine hydrochloride and lavender essential oil have been substantiated as parts of the studied medication. Study of acute toxicity of the developed dosage form has set that it belongs to the IV class of low-toxic substances due to the standard classification of K.K. Sidorova.Conclusion. This testifies the correctness of the choice of drug active ingredients and their concentrations.

Geumeunyoungji-tang Inhibits Serum IgE Level in Mouse Dermatitis Induced by 2,4-dinitrofluorobenzene

Lonicerae Flos containing formulation, Geumeumyoungji-tang (GYT), is an herbal prescription prepared using 5 different herbal drugs, namely, Lonicerae Flos, Ganoderma, Lactucae Herba, Xanthii Fructus, and Smilacis Rhizoma. This study was focused on the investigation of the pharmacological effects of GYT on allergic reactions. As the first step of the study, GYT was administered BALB/c mice which were sensitized by 2,4-dinitrofluorobenzene (DNFB). As the result GYT ameliorated dermatitis provoked by DNFB. The serum IgE level of the DNFB sensitized-mouse was significantly decreased when GYT was administered. In order to confirm the moderating effect of this prescription on allergic reaction, GYT was pretreated to human mast cells (HMC-1) before they were stimulated by phorbol-12-myristate 13-acetate plus calcium ionophore A23187 (PMACI). GYT suppressed secretion of inflammatory cytokines, interleukin (IL)-6 and IL-8, from HMC-1. Additionally, pretreatment of GYT showed regulating effect on COX-2 expression. Collectively, these findings provide insights into the pharmacological actions of GYT as a potential agent for treatment of allergic dermatitis.

Calcineurin inhibitors in the treatment of allergic dermatitis

To review the role of calcineurin inhibitors in the treatment of allergic dermatitis, focusing on mechanisms of action, efficacy and topical and systemic adverse effects. Articles written in English and published in MEDLINE using the following keywords: pimecrolimus, tacrolimus, calcineurin inhibitors. Original articles that presented controlled and open studies for assessing efficacy, tolerability and adverse effects were selected. Review articles and case series were also evaluated; the latter was only considered for assessing adverse effects. The official websites of the Food and Drug Administration and of manufacturers of calcineurin inhibitors were also used. The data showed that calcineurin inhibitors are efficient in the treatment of mild to severe atopic dermatitis, leading to improvement in symptoms, reduction in number of attacks and need of topical corticotherapy. Calcineurin inhibitors have good tolerability and few topical adverse effects. To date, there has been no evidence to support higher prevalence of neoplasia in patients using these drugs; however, an adequate pharmacovigilance system has been set up to assess this aspect. Calcineurin inhibitors, which are a new drug class in the treatment of allergic dermatitis, are efficient, well tolerated and have few adverse effects. Calcineurin inhibitors should always be used according to recommended guidelines, and patients should always be followed by the physician during and after their administration.

Involvement of cannabinoid CB 2 receptors in the IgE-mediated triphasic cutaneous reaction in mice

Involvement of cannabinoid CB 2 receptors in the IgE-mediated cutaneous reaction was investigated. Epicutaneous challenge with 2,4-dinitrofluorobenzene caused a triphasic swelling in the ear of BALB/c and C57BL/6 mice passively sensitized with anti-dinitrophenol IgE. Peak responses of the ear swelling appeared at 1 h, 24 h, and 8 days after the challenge in both strains of mice. In contrast, cannabinoid CB 2 receptor-deficient mice failed to exhibit the obvious triphasic ear swelling observed in wild-type mice. Oral administration of cannabinoid CB 2 receptor antagonist/inverse agonists [ N-(benzo[1,3]dioxol-5-ylmethyl)-7-methoxy-2-oxo-8-pentyloxy-1,2-dihydroquinoline-3-carboxamide] (JTE-907) and { N-[(1S)- endo-1,3,3-trimethylbicyclo[2,2,1]heptan-2yl]5-(4-chloro-3-methyl-phenyl)-1-(4-methylbenzyl)pyrazole-3-carboxamide} (SR144528) at doses of 0.1–10 mg/kg significantly and dose-dependently suppressed all three phases of ear swelling in BALB/c mice. Interestingly, epicutaneous treatment with an ether-linked analogue of endogenous cannabinoids, 2-arachidonoylglycerol, caused an ear swelling that could be detected at 1 h, 24 h, and 8 days after treatment of both BALB/c and C57BL/6 mice. These results suggest that cannabinoid CB 2 receptors are involved in induction of the triphasic cutaneous reaction mediated by IgE, and that cannabinoid CB 2 receptor antagonist/inverse agonists may serve as anti-allergic agents in the treatment of allergic dermatitis.